- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- America's 10 Favorite Fast-Food Burgers
Iclusig may find use in other cancers and '113 is better than the market believes.
Through four reverse stock splits, Cell Therapeutics has lost 99% of its value.
Instead of selling stock whenever the wind blows, biotech execs should be buying.
The strange but true tale of a beleaguered, bankrupt biotech firm with 100 quadrillion shares outstanding.
How best to invest in the next important clinical trial catalyst facing Celgene.